Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetate, and uses thereof

Abstract

Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided.

1 .- 9 . (canceled) 
     
     
         10 . A crystalline polymorph of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate: 
       
         
           
           
               
               
           
         
         characterized by peaks at 4.22, 8.51, and 16.95° 2θ±0.1° 2θ. 
       
     
     
         11 . The crystalline polymorph of  claim 10 , further characterized by a peak at 12.80° 2θ±0.1° 2θ. 
     
     
         12 . The crystalline polymorph of  claim 10  that exhibits an x-ray powder diffraction pattern substantially the same as the x-ray powder diffraction pattern shown in  FIG. 5 . 
     
     
         13 . The crystalline polymorph of  claim 10 , characterized by an endothermic point onset, as determined by differential scanning calorimetry at about 173° C. 
     
     
         14 . The crystalline polymorph of  claim 13  characterized by a differential scanning calorimetry pattern substantially the same as the differential scanning calorimetry pattern shown in  FIG. 6 . 
     
     
         15 . (canceled) 
     
     
         16 . A solid pharmaceutical composition comprising:
 an effective amount of the crystalline polymorph of  claim 10  as an active ingredient; and   at least one excipient or carrier.   
     
     
         17 . A method for treating or preventing hyperuricemia, or a disease caused by elevated uric acid levels, comprising administering an effective amount of the crystalline polymorph of  claim 10 . 
     
     
         18 . A method for treating or preventing gout comprising administering an effective amount of the crystalline polymorph of  claim 10 . 
     
     
         19 .- 46 . (canceled) 
     
     
         47 . A solid pharmaceutical composition comprising:
 an effective amount of the crystalline polymorph of  claim 13  as an active ingredient; and   at least one excipient or carrier.   
     
     
         48 . A method for treating or preventing hyperuricemia, or a disease caused by elevated uric acid levels, comprising administering an effective amount of the crystalline polymorph of  claim 13 . 
     
     
         49 . A method for treating or preventing gout comprising administering an effective amount of the crystalline polymorph of  claim 13 .